Apnimed
  • About
    • Apnimed Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Obstructive Sleep Apnea
  • Our Science
    • Publications
  • Clinical Research
    • Expanded Access Policy
  • Pipeline
  • News
    • Events
    • Insights
  • Contact Us
Select Page

An Introduction to Obstructive Sleep Apnea (3 of 3): The Search for Neurotransmitters That Play a Role in OSA Pathophysiology

Jun 21, 2022

By Luigi Taranto Montemurro, MD, CSO of Apnimed and David P. White, MD, SVP Medical Affairs, Apnimed Research has shown that patients with obstructive sleep apnea (OSA) share the anatomical disadvantage of a narrow upper airway that is prone to collapse during sleep....

An Introduction to Obstructive Sleep Apnea (2 of 3): More Than Just Anatomy

May 10, 2022

By Luigi Taranto Montemurro, MD, CSO of Apnimed and David P. White, MD, SVP Medical Affairs, Apnimed In our first article, we discussed the pressing need for pharmaceutical treatment options to treat obstructive sleep apnea (OSA) and how the complex anatomy and...

An Introduction to Obstructive Sleep Apnea (1 of 3): Development of Potential Pharmaceutical Treatment Options

Apr 12, 2022

By Luigi Taranto Montemurro, MD, CSO of Apnimed and David P. White, MD, SVP Medical Affairs, Apnimed It’s a familiar experience for many of us: a sleeping partner who snores, stops breathing or gasps for air. But we may not be familiar with these as potential signs of...

News

  • 2020
  • 2021
  • 2022
  • 2023
  • Events
  • Insights
  • Past Events
  • About
  • Obstructive Sleep Apnea
  • Our Science
  • Clinical Research
  • Pipeline
  • News
  • Careers
  • Contact Us
  • Twitter

Privacy Policy | Terms and Conditions

©2023 Apnimed. All rights reserved. Apnimed is a Cambridge, MA-based clinical-stage company dedicated to the discovery of novel therapies for sleep apnea and related disorders. The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.